340B Report, an independent news organization covering the 340B drug pricing program, is holding its first event—a May 18 webinar about implementing drug manufacturers’ controversial new rules on 340B contract pharmacies. It is an exclusive and free benefit for paid subscribers to 340B Report.
Understanding and complying with these first-of-their-kind policies is hard, 340B covered entities say. Getting help also is hard, they add. Two usual advisers to entities on such matters—the federal government and trade associations—believe that what the manufacturers are doing is illegal and they do not want to abet drug makers’ policies. Many entities say, though, that as a practical matter they must comply, and they desperately need guidance.
340B Report is holding its first event—a May 18 webinar about implementing drug manufacturers’ controversial new rules on 340B contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
